{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T02:54:10Z","timestamp":1794020050215,"version":"4.8.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T00:00:00Z","timestamp":1740700800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T00:00:00Z","timestamp":1740700800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-90937-w","type":"journal-article","created":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T14:21:37Z","timestamp":1740752497000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Efficacy and safety of rituximab in anti-MuSK myasthenia Gravis: a systematic review and meta-analysis"],"prefix":"10.1038","volume":"15","author":[{"given":"Siripong","family":"Chayanopparat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Perasin","family":"Banyatcharoen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiraporn","family":"Jitprapaikulsan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekdanai","family":"Uawithya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natnasak","family":"Apiraksattayakul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasinee","family":"Viarasilpa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,28]]},"reference":[{"key":"90937_CR1","doi-asserted-by":"publisher","first-page":"154","DOI":"10.29399\/npa.27315","volume":"58","author":"F Deymeer","year":"2021","unstructured":"Deymeer, F. History of myasthenia Gravis revisited. Noro Psikiyatr Ars. 58, 154\u2013162. https:\/\/doi.org\/10.29399\/npa.27315 (2021).","journal-title":"Noro Psikiyatr Ars"},{"key":"90937_CR2","doi-asserted-by":"publisher","first-page":"86","DOI":"10.3389\/fnmol.2020.00086","volume":"13","author":"M Takamori","year":"2020","unstructured":"Takamori, M. & Myasthenia Gravis From the viewpoint of pathogenicity focusing on acetylcholine receptor clustering, Trans-Synaptic homeostasis and synaptic stability. Front. Mol. Neurosci. 13, 86. https:\/\/doi.org\/10.3389\/fnmol.2020.00086 (2020).","journal-title":"Front. Mol. Neurosci."},{"key":"90937_CR3","doi-asserted-by":"publisher","unstructured":"Dresser, L., Wlodarski, R., Rezania, K. & Soliven, B. Myasthenia Gravis: epidemiology, pathophysiology and clinical manifestations. J. Clin. Med. 10 https:\/\/doi.org\/10.3390\/jcm10112235 (2021).","DOI":"10.3390\/jcm10112235"},{"key":"90937_CR4","doi-asserted-by":"publisher","first-page":"103","DOI":"10.3949\/ccjm.90a.22017","volume":"90","author":"JA Morren","year":"2023","unstructured":"Morren, J. A. & Li, Y. Myasthenia Gravis: frequently asked questions. Cleve Clin. J. Med. 90, 103\u2013113. https:\/\/doi.org\/10.3949\/ccjm.90a.22017 (2023).","journal-title":"Cleve Clin. J. Med."},{"issue":"6","key":"90937_CR5","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.3390\/jcm11061597","volume":"11","author":"MK Alhaidar","year":"2022","unstructured":"Alhaidar, M. K., Abumurad, S., Soliven, B. & Rezania, K. Current treatment of myasthenia Gravis. J. Clin. Med. 11 (6), 1597 (2022).","journal-title":"J. Clin. Med."},{"key":"90937_CR6","doi-asserted-by":"publisher","first-page":"1212757","DOI":"10.3389\/fimmu.2023.1212757","volume":"14","author":"AG Vakrakou","year":"2023","unstructured":"Vakrakou, A. G. et al. Immunotherapies in MuSK-positive myasthenia Gravis; an IgG4 antibody-mediated disease. Front. Immunol. 14, 1212757. https:\/\/doi.org\/10.3389\/fimmu.2023.1212757 (2023).","journal-title":"Front. Immunol."},{"key":"90937_CR7","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1136\/jnnp-2019-322606","volume":"91","author":"V Di Stefano","year":"2020","unstructured":"Di Stefano, V. et al. Rituximab in achr subtype of myasthenia Gravis: systematic review. J. Neurol. Neurosurg. Psychiatry. 91, 392\u2013395. https:\/\/doi.org\/10.1136\/jnnp-2019-322606 (2020).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"90937_CR8","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1001\/jamaneurol.2022.2887","volume":"79","author":"F Piehl","year":"2022","unstructured":"Piehl, F. et al. Efficacy and safety of rituximab for New-Onset generalized myasthenia Gravis. JAMA Neurol. 79, 1105 (2022).","journal-title":"JAMA Neurol."},{"key":"90937_CR9","doi-asserted-by":"publisher","first-page":"n160","DOI":"10.1136\/bmj.n160","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page, M. J. et al. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ 372, n160. https:\/\/doi.org\/10.1136\/bmj.n160 (2021).","journal-title":"BMJ"},{"key":"90937_CR10","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/s0003-4975(00)01595-2","volume":"70","author":"A Jaretzki","year":"2000","unstructured":"Jaretzki, A. et al. Myasthenia Gravis: recommendations for clinical research standards. Task force of the medical scientific advisory board of the myasthenia Gravis foundation of America. Ann. Thorac. Surg. 70, 327\u2013334. https:\/\/doi.org\/10.1016\/s0003-4975(00)01595-2 (2000).","journal-title":"Ann. Thorac. Surg."},{"key":"90937_CR11","unstructured":"Wells, G. A. & O\u2019Connell, S. B. D, et al. The NewcastleOttawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp"},{"key":"90937_CR12","doi-asserted-by":"publisher","first-page":"137561","DOI":"10.1016\/j.neulet.2023.137561","volume":"818","author":"X Yang","year":"2024","unstructured":"Yang, X. et al. Promising efficacy of Low-Dose rituximab in muscle specific kinase antibody positive myasthenia Gravis. Neurosci. Lett. 818, 137561. https:\/\/doi.org\/10.1016\/j.neulet.2023.137561 (2024).","journal-title":"Neurosci. Lett."},{"key":"90937_CR13","doi-asserted-by":"publisher","first-page":"120394","DOI":"10.1016\/j.jns.2022.120394","volume":"442","author":"JM Heckmann","year":"2022","unstructured":"Heckmann, J. M. A single low-dose rituximab infusion in severe chronic refractory myasthenia Gravis in resource-limited settings. J. Neurol. Sci. 442, 120394. https:\/\/doi.org\/10.1016\/j.jns.2022.120394 (2022).","journal-title":"J. Neurol. Sci."},{"issue":"1","key":"90937_CR14","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1097\/CND.0000000000000420","volume":"24","author":"JI Castiglione","year":"2022","unstructured":"Castiglione, J. I. et al. Long-Term remission with Low-Dose rituximab in myasthenia Gravis: a retrospective study. J. Clin. Neuromuscul. Dis. 24 (1), 18\u201325 (2022).","journal-title":"J. Clin. Neuromuscul. Dis."},{"key":"90937_CR15","doi-asserted-by":"publisher","first-page":"953","DOI":"10.2147\/NDT.S358851","volume":"18","author":"X Meng","year":"2022","unstructured":"Meng, X. et al. Efficacy and safety of Low-Dose rituximab in Anti-MuSK myasthenia Gravis patients: A retrospective study. Neuropsychiatr Dis. Treat. 18, 953\u2013964. https:\/\/doi.org\/10.2147\/NDT.S358851 (2022).","journal-title":"Neuropsychiatr Dis. Treat."},{"key":"90937_CR16","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1186\/s12883-021-02439-7","volume":"21","author":"S Zhao","year":"2021","unstructured":"Zhao, S. et al. Clinical features, treatment and prognosis of musk antibody-associated myasthenia Gravis in Northwest China: a single-centre retrospective cohort study. BMC Neurol. 21, 428. https:\/\/doi.org\/10.1186\/s12883-021-02439-7 (2021).","journal-title":"BMC Neurol."},{"key":"90937_CR17","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1002\/mus.27233","volume":"63","author":"Y Zhou","year":"2021","unstructured":"Zhou, Y. et al. Short-term effect of low-dose rituximab on myasthenia Gravis with muscle-specific tyrosine kinase antibody. Muscle Nerve. 63, 824\u2013830. https:\/\/doi.org\/10.1002\/mus.27233 (2021).","journal-title":"Muscle Nerve"},{"key":"90937_CR18","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1111\/ene.14391","volume":"27","author":"A Dos Santos","year":"2020","unstructured":"Dos Santos, A. et al. Efficacy and safety of rituximab in myasthenia Gravis: a French multicentre real-life study. Eur. J. Neurol. 27, 2277\u20132285. https:\/\/doi.org\/10.1111\/ene.14391 (2020).","journal-title":"Eur. J. Neurol."},{"key":"90937_CR19","doi-asserted-by":"publisher","first-page":"116690","DOI":"10.1016\/j.jns.2020.116690","volume":"411","author":"T Litchman","year":"2020","unstructured":"Litchman, T. et al. Differential response to rituximab in anti-AChR and anti-MuSK positive myasthenia Gravis patients: a single-center retrospective study. J. Neurol. Sci. 411, 116690. https:\/\/doi.org\/10.1016\/j.jns.2020.116690 (2020).","journal-title":"J. Neurol. Sci."},{"key":"90937_CR20","doi-asserted-by":"publisher","first-page":"175628641987118","DOI":"10.1177\/1756286419871187","volume":"12","author":"K Choi","year":"2019","unstructured":"Choi, K. et al. Repeated low-dose rituximab treatment based on the assessment of Circulating B cells in patients with refractory myasthenia Gravis. Ther. Adv. Neurol. Disord. 12, 1756286419871187. https:\/\/doi.org\/10.1177\/1756286419871187 (2019).","journal-title":"Ther. Adv. Neurol. Disord"},{"key":"90937_CR21","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1007\/s00415-019-09191-6","volume":"266","author":"R Topakian","year":"2019","unstructured":"Topakian, R. et al. High efficacy of rituximab for myasthenia Gravis: a comprehensive nationwide study in Austria. J. Neurol. 266, 699\u2013706. https:\/\/doi.org\/10.1007\/s00415-019-09191-6 (2019).","journal-title":"J. Neurol."},{"key":"90937_CR22","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1016\/j.nmd.2019.06.002","volume":"29","author":"RH Roda","year":"2019","unstructured":"Roda, R. H., Doherty, L. & Corse, A. M. Stopping oral steroid-sparing agents at initiation of rituximab in myasthenia Gravis. Neuromuscul. Disord. 29, 554\u2013561. https:\/\/doi.org\/10.1016\/j.nmd.2019.06.002 (2019).","journal-title":"Neuromuscul. Disord"},{"key":"90937_CR23","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1212\/WNL.0b013e3182407982","volume":"78","author":"J Diaz-Manera","year":"2012","unstructured":"Diaz-Manera, J. et al. Long-lasting treatment effect of rituximab in musk myasthenia. Neurology 78, 189\u2013193. https:\/\/doi.org\/10.1212\/WNL.0b013e3182407982 (2012).","journal-title":"Neurology"},{"key":"90937_CR24","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.jneuroim.2006.03.016","volume":"175","author":"S Jha","year":"2006","unstructured":"Jha, S. et al. Myasthenia Gravis induced in mice by immunization with the Recombinant extracellular domain of rat muscle-specific kinase (MuSK). J. Neuroimmunol. 175, 107\u2013117. https:\/\/doi.org\/10.1016\/j.jneuroim.2006.03.016 (2006).","journal-title":"J. Neuroimmunol."},{"key":"90937_CR25","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1172\/JCI21545","volume":"116","author":"K Shigemoto","year":"2006","unstructured":"Shigemoto, K. et al. Induction of myasthenia by immunization against muscle-specific kinase. J. Clin. Invest. 116, 1016\u20131024. https:\/\/doi.org\/10.1172\/JCI21545 (2006).","journal-title":"J. Clin. Invest."},{"key":"90937_CR26","doi-asserted-by":"publisher","first-page":"613","DOI":"10.3389\/fimmu.2020.00613","volume":"11","author":"M Marino","year":"2020","unstructured":"Marino, M. et al. Long-Lasting Rituximab-Induced reduction of Specific-But not Total-IgG4 in MuSK-Positive myasthenia Gravis. Front. Immunol. 11, 613. https:\/\/doi.org\/10.3389\/fimmu.2020.00613 (2020).","journal-title":"Front. Immunol."},{"key":"90937_CR27","doi-asserted-by":"publisher","first-page":"736190","DOI":"10.3389\/fneur.2021.736190","volume":"12","author":"C Zhao","year":"2021","unstructured":"Zhao, C. et al. Effectiveness and safety of rituximab for refractory myasthenia Gravis: A systematic review and Single-Arm Meta-Analysis. Front. Neurol. 12, 736190. https:\/\/doi.org\/10.3389\/fneur.2021.736190 (2021).","journal-title":"Front. Neurol."},{"key":"90937_CR28","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1001\/jamaneurol.2019.1686","volume":"76","author":"B Olsson","year":"2019","unstructured":"Olsson, B. et al. Infection risks among patients with multiple sclerosis treated with Fingolimod, natalizumab, rituximab, and injectable therapies. JAMA Neurol. 76, 1137\u20131143. https:\/\/doi.org\/10.1001\/jamaneurol.2019.1686 (2019).","journal-title":"JAMA Neurol."},{"key":"90937_CR29","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.3899\/jrheum.150051","volume":"42","author":"RF Van Vollenhoven","year":"2015","unstructured":"Van Vollenhoven, R. F., Fleischmann, R. M., Furst, D. E., Lacey, S. & Lehane, P. B. Longterm safety of rituximab: final report of the rheumatoid arthritis global clinical trial program over 11 years. J. Rhuematol. 42, 1761\u20131766 (2015).","journal-title":"J. Rhuematol."},{"key":"90937_CR30","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","volume":"16","author":"JF Howard","year":"2017","unstructured":"Howard, J. F. et al. Safety and efficacy of Eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia Gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurol. 16, 976\u2013986 (2017).","journal-title":"Lancet Neurol."},{"key":"90937_CR31","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","volume":"20","author":"JF Howard","year":"2021","unstructured":"Howard, J. F. et al. Safety, efficacy, and tolerability of Efgartigimod in patients with generalised myasthenia Gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 20, 526\u2013536 (2021).","journal-title":"Lancet Neurol."},{"key":"90937_CR32","doi-asserted-by":"publisher","first-page":"e00378","DOI":"10.1016\/j.neurot.2024.e00378","volume":"21","author":"JF Howard","year":"2024","unstructured":"Howard, J. F. et al. Subcutaneous Efgartigimod PH20 in generalized myasthenia Gravis: A phase 3 randomized noninferiority study (ADAPT-SC) and interim analyses of a long-term open-label extension study (ADAPT-SC+). Neurotherapeutics 21, e00378 (2024).","journal-title":"Neurotherapeutics"},{"key":"90937_CR33","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S1474-4422(23)00077-7","volume":"22","author":"V Bril","year":"2023","unstructured":"Bril, V. et al. Safety and efficacy of Rozanolixizumab in patients with generalised myasthenia Gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study. Lancet Neurol. 22, 383\u2013394 (2023).","journal-title":"Lancet Neurol."},{"key":"90937_CR34","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.1182\/blood.V100.6.2257","volume":"100","author":"LE Van Der Kolk","year":"2002","unstructured":"Van Der Kolk, L. E., Baars, J. W., Prins, M. H. & Van Oers, M. H. J. Rituximab treatment results in impaired secondary humoral immune responsiveness. Blood 100, 2257\u20132259 (2002).","journal-title":"Blood"},{"key":"90937_CR35","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1093\/qjmed\/hcu094","volume":"107","author":"M Makatsori","year":"2014","unstructured":"Makatsori, M. et al. Hypogammaglobulinaemia after rituximab treatment\u2013incidence and outcomes. QJM 107, 821\u2013828 (2014).","journal-title":"QJM"},{"key":"90937_CR36","doi-asserted-by":"crossref","unstructured":"Nie, Y. et al. Hypogammaglobulinemia and infection events in patients with autoimmune diseases treated with rituximab: 10 years Real-Life experience. J. Clin. Immunol. 44, (2024).","DOI":"10.1007\/s10875-024-01773-y"},{"key":"90937_CR37","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1093\/cid\/ciaa131","volume":"72","author":"E Gkrania-Klotsas","year":"2020","unstructured":"Gkrania-Klotsas, E. & Kumararatne, D. S. Serious infectious complications after rituximab therapy in patients with autoimmunity: is this the final word? Clin. Infect. Dis. 72, 738\u2013742 (2020).","journal-title":"Clin. Infect. Dis."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-90937-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-90937-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-90937-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T14:21:40Z","timestamp":1740752500000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-90937-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,28]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["90937"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-90937-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,28]]},"assertion":[{"value":"5 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"7219"}}